What smart money is saying about Zoetis Inc.
8 funds in our archive have pitched Zoetis Inc. — most recently Acatis in December 2026.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Get an email when a fund writes about it
Position history
Between Q4 2024 and Q4 2026, 16 fund letters reported a position in Zoetis Inc. — 3 opened or added to the position, 7 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q4 2026 | 0 | 0 | 0 | 1 |
| Q2 2026 | 16 | 3 | 7 | 3 |
| Q2 2025 | 0 | 0 | 0 | 2 |
| Q4 2024 | 0 | 0 | 0 | 2 |
Fund activity · 16 positions · 10 moves
- ExitedFundsmith Equity FundJune 2026
“We exited or have started exiting: Atlas Copco, Coloplast, Essilor Luxottica, Intuit, LVMH, Magnum Ice Cream, Mettler-Toledo, Nike, Novo Nordisk, Otis, Unilever, Wolters Kluwer, and Zoetis.”
Zoetis Inc. - ExitedAve Maria FundsJune 2026
“In the second quarter, the fund exited investments in Accenture, Alcon, Copart, TIC Solutions, and Zoetis.”
Zoetis Inc. - June 2026
“During the quarter, we were unusually busy. We bought Hermès and sold Tractor Supply Company, Zoetis, and CDW.”
Zoetis Inc. - TrimmedACATIS InvestmentJune 2026
“In May, the fund delivered a +1.0% return in a divided market environment: while the AI supercycle boosted the technology sector, interest rate pressure and macroeconomic uncertainties weighed on defensive sectors. The biggest winners were ASML (+13.3%), Microsoft (+11.0%) and Salesforce (+8.8%), all of which benefited from strong AI-driven demand. The good performance of software stocks in particular shows that there is still potential for a revaluation. Zoetis (-32.1%) recorded the sharpest decline, where regulatory concerns about side effects of high-selling osteoarthritis drugs and subdued demand dynamics signi- ficantly shook investor confidence.”
Zoetis Inc. - June 2026
“Zoetis (-32.1%) recorded the sharpest decline, where regulatory concerns about side effects of high-selling osteoarthritis drugs and subdued demand dynamics signi- ficantly shook investor confidence.”
Zoetis Inc. - New positionTweedy, Browne Fund Inc.June 2026
“As mentioned last quarter, the investment strategy for the newly renamed Tweedy, Browne Buybacks . Dividends + Value Fund (formerly the Worldwide High Dividend Yield Value Fund), was modestly adjusted to emphasize investment in companies that pay an attractive dividend and/or have initiated buybacks of their shares, when those shares are trading at discounts to underlying value — including undervaluation based on proprietary combinations of various numerical value oriented investment characteristics, a value score, and qualitative assessments. The Fund no longer requires an above average dividend. The expanded mandate opened the door for several new purchases that would not have qualified under the former mandate. This included the establishment of new positions in Alliance Resource Partners, Autotrader Group, Berkeley Group Holdings, Capgemini, Euronet Worldwide Inc, Koito Manufacturing Co, Krafton Inc, Metropolitan Bank & Trust Company, Sega Sammy Holdings Inc, Suzuken Co Ltd, Western Union, Winpak Ltd, and Zoetis, Inc.”
Zoetis Inc. - June 2026
“ We exited Zoetis in May.”
Zoetis Inc. - June 2026
“ We exited Zoetis in May. We were attracted to the investment due to its position as the largest pure-play animal health company, benefiting from significant scale in R&D and as the highest-quality marketer to veterinarians and livestock producers, which increases switching costs. The company had further shifted its business mix meaningfully toward a higher and more profitable contribution from its companion animal segment. Our investment in Zoetis began to face increased growth headwinds in 2025 due to incremental competition in its industry-leading dermatology and Simparica Trio products. Additionally, the launch of Librela—the first available therapy for osteoarthritis pain in dogs—underperformed our expectations. Furthermore, we have observed increased competition across Zoetis’s main franchises and, most recently, Zoetis also saw generic competition in therapeutic categories. Several concerns have emerged: (1) despite the high barriers to entry in animal health, competition in the sector has intensified during our ownership; (2) we do not have enough visibility on their pipeline to assess the path of future contribution at this point; and (3) we misinterpreted Zoetis’s ability to contribute to the portfolio from a deferrable demand perspective, as it did not deliver the defensiveness we expected. As such, we see our investment thesis in Zoetis as broken and have fully exited the position.”
Zoetis Inc. - New positionMoon Capital U.S. Equity StrategyJune 2026
“JULY 2026 5 Portfolio addition: Zoetis (ZTS) We added one new stock to the portfolio last quarter, Zoetis.”
Zoetis Inc. - June 2026
“On the negative side, animal health company Zoetis was our largest detractor in terms of performance in the second quarter after reporting disappointing quarterly results.”
Zoetis Inc. - New positionBrandes Global Equity FundJune 2026
“The investment committee initiated a new position in U.S.- based animal health care firm Zoetis.”
Zoetis Inc. - June 2026
“• Shares of Zoetis, an animal health company, underperformed after the company reported flat organic revenue growth and lowered full-year guidance amid softer US companion-animal demand, fewer veterinary visits and a more competitive market.”
Zoetis Inc. - June 2026
“• Shares of Zoetis, an animal health company, underperformed after the company reported flat organic revenue growth and lowered full-year guidance amid softer US companion-animal demand, fewer veterinary visits and a more competitive market.”
Zoetis Inc. - June 2026
“• Shares of Zoetis, an animal health company, underperformed after the company reported flat organic revenue growth and lowered full-year guidance amid softer US companion-animal demand, fewer veterinary visits and a more competitive market.”
Zoetis Inc. - June 2026
“Key detractors • Shares of Zoetis, an animal health company, underperformed after the company reported flat organic revenue growth and lowered full-year guidance amid softer US companion-animal demand, fewer veterinary visits and a more competitive market.”
Zoetis Inc. - June 2026
“Lastly, we eliminated our position in Zoetis.”
Zoetis Inc.
Also mentioned · 1
These funds discuss Zoetis Inc. — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedDiamond Hill Large Cap FundJune 2026
“• Shares of Zoetis, an animal health company, underperformed after the company reported flat organic revenue growth and lowered full-year guidance amid softer US companion-animal demand, fewer veterinary visits and a more competitive market.”
Zoetis Inc.
Fund coverage · 8 theses
- AcatisDecember 2026
Zoetis is a quality leader in animal health with strong sector tailwinds, high margins, and a below-average P/E presenting an entry opportunity.
Read the full thesis - Moon Capital U.S. Equity StrategyJune 2026
Zoetis is the world's largest pure-play animal health company, owned for its dominant competitive position, strong margins, durable growth prospects, and attractive valuation.
Read the full thesis Zoetis, Inc. Class A was originally attractive for scale and switching costs in animal health, but intensifying competition and weaker product launches broke the thesis.
Read the full thesis- Brandes Global Equity FundJune 2026
Zoetis is the global leader in animal health with strong returns on capital, secular growth tailwinds, high barriers to entry, and an attractive valuation opportunity.
Read the full thesis Zoetis is the world’s largest animal health company with a strong R&D focus and a promising product pipeline, maintaining growth despite market challenges.
Read the full thesis- Wedgewood PartnersJune 2025
Zoetis is well-positioned to benefit from the steady growth of the pet care industry, driven by increasing pet ownership, longer pet lifespans, and enhanced treatment options.
Read the full thesis - Brown AdvisoryDecember 2024
Zoetis is the global leader in animal health, excelling in R&D and innovation, with a strong market position that offers competitive advantages in a less crowded and regulated industry.
Read the full thesis - Platinium AMDecember 2024
Zoetis is the leading global innovator in animal medicine, with strong growth and promising new treatments for Osteoarthritis in pets, despite concerns over pricing and regulatory adjustments.
Read the full thesis
Read every full thesis on Zoetis Inc.
Unlock all 8 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→